Nexstim Receives System Order from Distributor in the Middle East
Nexstim
Nexstim Receives System Order from Distributor in the Middle East
Press release, Helsinki, 27 June 2025 at 9 AM (EEST)
Nexstim Receives System Order from Distributor in the Middle East
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a distributor for a clinic in the Middle East. The end customer is new to Nexstim.
The Nexstim Navigated Brain Stimulation (NBS) System 5 ordered includes a therapy module, allowing the system to be used for the treatment of major depression and chronic neuropathic pain. The end customer intends to use the system mainly in therapy and potentially also for research purposes.
Mikko Karvinen, CEO of Nexstim, comments: “With the hard work and expertise of both our international Nexstim team as well as our distributors, we have continued to achieve system sales to different kinds of customers in a large geographical area. Happy to see the efforts pay off as we near the end of the first half of the year.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
|
This release was sent by Inderes IR Distribution |
|
|
